A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Orthonika Awarded £1.34 Million Innovate UK Grant

To Accelerate Development of Its Total Meniscus Replacement Towards the Clinic

Orthonika Limited, a spin-out from Imperial College London, has been awarded a £1.34 million grant from Innovate UK, the UK’s innovation agency, to complete pre-clinical development and testing of its synthetic total meniscus replacement in preparation for the clinic.

Meniscus injury is severely debilitating, causing pain and restricted movement that limits everyday activities. Current treatment options are limited to suture repair or meniscal allografts, which are in short supply and lead to long waiting times. Where suture repair is not possible, the injured part or remaining meniscus is removed (meniscectomy) to alleviate symptoms in the short term. However, such patients are 14 times more likely to develop osteoarthritis. Meniscectomy has become the most common orthopedic surgical intervention worldwide, with nearly 2 million interventions performed each year. There are currently no approved total meniscus replacements for these patients.

Orthonika’s total meniscus replacement is an orthopedic implant for the knee joint that represents an entirely novel solution, replicating the structure and function of the native meniscus in a first-of-its-kind synthetic option for patients. The implant design is unique, featuring an inherent attachment mechanism incorporated into the underlying structure which allows for optimal load transfer and distribution in the knee joint during mobility. Orthonika’s implant aims to restore the biomechanical function of the meniscus to help reduce pain, improve mobility and ultimately delay the onset of osteoarthritis. It is intended to fill the gap between minimally invasive meniscus repair and total knee replacement.

“There is currently no widely available treatment solution that allows patients to return to a pain-free active lifestyle following meniscectomy,” said Maria Kristina Bartolo, Ph.D., Chief Technology Officer at Orthonika. “We are delighted that Innovate UK has recognised the potential for our novel total meniscus replacement to fulfill a significant unmet clinical need and further promote joint preservation.”

Dominique Kleyn, Co-Founder and Chief Operating Officer said: “This highly competitive award brings additional resource for Orthonika to further expand the team, engage with development partners and manufacturers, and accelerate plans to take our total meniscus replacement product into first in human studies.”

This is the fifth Innovate UK grant awarded to Orthonika, bringing total grant funding to £2 million. The company has also raised equity funding to further support its R&D efforts.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy